SOURCE: Leerink Swann & Company

June 30, 2005 06:00 ET

Leerink Swann & Company Initiates Coverage of Connetics Corporation (NASDAQ: CNCT)

BOSTON, MA -- (MARKET WIRE) -- June 30, 2005 -- Yesterday after the close, Senior Specialty Pharmaceuticals Analyst, Gary Nachman, resumed coverage of Connetics Corporation with an Outperform rating. His investment rating is based on his belief that Connetics' proprietary products and robust pipeline will produce solid earnings growth over the next several years. He thinks now is an attractive entry point after the sell-off in the stock following the recent Velac disappointment.

About Connetics Corporation

Connetics Corporation (NASDAQ: CNCT) develops and commercializes dermatology products for the treatment of acnes and psoriasis. Connetics has branded its proprietary foam drug delivery vehicle VersaFoam®. The company is headquartered in Palo Alto, California.

About Leerink Swann & Company

Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2004 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. MEDACorp includes thousands of biomedical professionals and practicing physicians. Leerink Swann & Company is a member NASD/SIPC.

Contact Information

  • Contact:
    John I. Fitzgerald
    Leerink Swann & Company
    (617) 918-4564